Biogen Inc. (FRA:IDP)
146.80
+0.80 (0.55%)
At close: Jan 30, 2026
Biogen Revenue
Biogen had revenue of $2.53B USD in the quarter ending September 30, 2025, with 2.79% growth. This brings the company's revenue in the last twelve months to $10.07B, up 4.77% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$10.07B
Revenue Growth
+4.77%
P/S Ratio
2.59
Revenue / Employee
$1.32M
Employees
7,605
Market Cap
22.21B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
| Dec 31, 2018 | 13.45B | 1.18B | 9.61% |
| Dec 31, 2017 | 12.27B | 825.10M | 7.21% |
| Dec 31, 2016 | 11.45B | 685.00M | 6.36% |
| Dec 31, 2015 | 10.76B | 1.06B | 10.93% |
| Dec 31, 2014 | 9.70B | 2.77B | 39.97% |
| Dec 31, 2013 | 6.93B | 1.42B | 25.66% |
| Dec 31, 2012 | 5.52B | 467.83M | 9.27% |
| Dec 31, 2011 | 5.05B | 332.21M | 7.04% |
| Dec 31, 2010 | 4.72B | 339.08M | 7.75% |
| Dec 31, 2009 | 4.38B | 279.84M | 6.83% |
| Dec 31, 2008 | 4.10B | 925.89M | 29.19% |
| Dec 31, 2007 | 3.17B | 488.57M | 18.21% |
| Dec 31, 2006 | 2.68B | 260.55M | 10.76% |
| Dec 31, 2005 | 2.42B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mainova AG | 3.89B |
| Gelsenwasser AG | 3.36B |
| Paul Hartmann AG | 2.44B |
| Lechwerke AG | 1.06B |
| tonies SE | 510.38M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |
Biogen News
- 17 days ago - Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more - CNBC
- 17 days ago - Biogen Sees $1.26 Per Share Impact From IPR&D, Milestone Expenses In Q4 - Nasdaq
- 17 days ago - Biogen (BIIB) Anticipates Q4 Earnings Impact Due to R&D Costs - GuruFocus
- 17 days ago - Biogen sees Q4 IPR&D impacts on EPS by ~$1.26/share - Seeking Alpha
- 17 days ago - Biogen (BIIB) Anticipates Significant Q4 2025 Financial Impact from R&D Charges - GuruFocus
- 18 days ago - Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy - CNBC
- 19 days ago - Biogen Receives European Nod For High-Dose Regimen Of SPINRAZA In Spinal Muscular Atrophy - Nasdaq
- 19 days ago - Biogen Gains EU Approval For High-Dose SPINRAZA Regimen In SMA - Nasdaq